Lilly, Anthem show high risk, high reward strategy can pay off
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Eli Lilly & Co.
Articles
Lilly faces moment of truth this week
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Indiana’s medical research ‘trade deficit’
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Fate of Eli Lilly’s potential $2B blockbuster insulin hangs on side effects
Lilly’s basal insulin peglispro proved more effective than the $7 billion blockbuster Lantus at controlling diabetics’ blood sugar, but it also had greater effect on patients’ livers and hearts. Analysts are unsure of its future.
How ‘losing’ the headquarters of two promising drug firms could help Indiana
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
Hoosier docs enjoy more than $40M a year from drug, device firms
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
Killing obesity without coercion
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
CEO Roundup: We’re not your father’s health care company anymore
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Obamacare’s effects on Lilly: Modest pain, no gain
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
Top 4 questions for Hoosier health care after GOP takes control of Congress
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.
Lechleiter: It’s morning at Eli Lilly
Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.
More patients help drug firms pass ‘valley of death’
In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.
Most drug money in Indiana funds research. Is that good?
With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That’s not the same thing as paying to market drugs, but it’s hardly without controversy.
Indy patients love their doctors
Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Doctors’ drug money
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
Five things I learned from the Medicare doctor payments
From this week’s historic data dump, I learned who the top 20 recipients of Medicare payments are in Indianapolis (hint: mostly labs, ambulances and eye surgeons). But the real takeaway is that meaningful price information about doctors is still a long way away.
Lilly shares hit all-time high for the John Lechleiter era
Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they’ve ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
Life sciences jobs pack 2-for-1 punch
While life sciences companies don’t rack up huge jobs numbers, their relatively high pay means that every job they create is worth two in the rest of the private sector.
No one likes Obamacare
Obamacare has officially arrived, but both conservatives and liberals are calling it awful. That means the real debate over health reform is just beginning.
Health care has priced itself out of its own market
It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.